Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older

Shan Huang; Shuyu Zheng; Tuotuo Gong; Hongbing Ma; Yue Ke; Songchuan Zhao; Wenyu Wang; Lijun Jia; Xiaozhi Zhang

doi:10.18632/oncotarget.22884

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older

Shan Huang, Shuyu Zheng, Tuotuo Gong, Hongbing Ma, Yue Ke, Songchuan Zhao, Wenyu Wang, Lijun Jia and Xiaozhi Zhang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:112094-112102. https://doi.org/10.18632/oncotarget.22884

Metrics: PDF 1082 views | HTML 1798 views | ?

Abstract

Shan Huang1, Shuyu Zheng2, Tuotuo Gong2, Hongbing Ma1, Yue Ke1, Songchuan Zhao3, Wenyu Wang4, Lijun Jia5 and Xiaozhi Zhang2

1Department of Radiotherapy, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China

2Department of Radiotherapy, First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China

3Department of Spine Surgery, Honghui Hospital, Health Science Center, Xi’an Jiaotong University, Xi’an, China

4Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

5Department of Oncology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China

Correspondence to:

Xiaozhi Zhang, email: [email protected]

Keywords: esophageal cancer; aged 80 and older; radiotherapy; survival; stage

Received: June 27, 2017 Accepted: November 15, 2017 Published: December 04, 2017

ABSTRACT

Purpose: To evaluate the survival benefit of radiotherapy (RT) in esophageal cancer (EC) patients aged ≥ 80.

Materials and Methods: Records for all EC patients aged ≥ 65 years were extracted from the Surveillance, Epidemiology, and End Results database. Chi-square test compared the characteristic and treatment between patients aged ≥ 80 with those aged 65–79. Focusing on patients aged ≥ 80, we employed multivariable logistic regression to identify the association between selection of RT and patients’ characteristics. Survival curve was employed to visualize the survival rate and multivariable Cox proportional hazard model was established to quantify the effect of RT on overall survival (OS) and cancer special survival (CSS).

Results: Patients aged ≥ 80 were more likely to be white male and have localized EC (all P < 0.001). Selection of RT in patients aged ≥ 80 were associated with cancer histology (P < 0.001), grade (P = 0.024) and stage (P < 0.001). RT significantly improved the OS (hazard ratio(HR) = 0.717) and CSS (HR = 0.722) (all P < 0.001). Further stratified analysis found the improvement were only significant in the localized (OS HR = 0.662; CSS HR=0.652) and regional stage patients (OS HR = 0.571; CSS HR = 0.581) (all P < 0.001).

Conclusions: Our study suggested EC patients aged ≥ 80 benefit from RT only if the cancer is in localized/regional stage.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22884

Publication Alerts

Clinical Research Papers:

Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older

Abstract